Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study
Sandra Huynh(Assistance Publique – Hôpitaux de Paris), Julie Delyon(Inserm), M.‐T. Leccia(Centre Hospitalier Universitaire de Grenoble), O. Dereure(Beth Israel Deaconess Medical Center), Wendy Lefevre(Inserm), Célèste Lebbé(Inserm), Brigitte Dréno(Nantes Université), F. Brunet‐Possenti(Inserm), E. Maubec(Inserm), F. Aubin(Centre Hospitalier Universitaire de Besançon), M. Boileau(Université de Lille), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Laurent Mortier, Jean‐Philippe Arnault(Centre Hospitalier Universitaire Amiens-Picardie), M. Beylot‐Barry(Université de Bordeaux)
Cited by 21
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
|Journal of Clinical Oncology|2000|1.3k